Data from several laboratories have shown that the α7-nAChR antagonists could be considered as potential anticancer agents (Trombino et al., 2004; Russo et al., 2006; Grozio et al., 2008; Paleari et al., 2008a,b), since antagonists (e.g. d-tubocurarine or snake’s long neurotoxin) have an inhibitory effect on tumor growth by binding to α7-nAChR (Cesario et al., 2004; Grozio et al., 2007; Catassi et al., 2008; Grozio et al., 2008; Paleari et al., 2008a,b). This evidence concerns the gene CHRNA7 and neoplasm.